Evidence · Randomised trial
Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
- Medical
- Neurology
- Nursing
- Status epilepticus
This paper is from 2019, more than five years ago. Newer evidence may have been published since.
Summary
EcLiPSE was a UK multicentre, open-label randomised trial comparing intravenous levetiracetam with phenytoin as second-line treatment for paediatric convulsive status epilepticus in children aged 6 months to under 18 years presenting to emergency departments. The primary outcome was time from randomisation to cessation of convulsive status epilepticus, with 286 treated participants analysed. Levetiracetam was not statistically superior to phenytoin, but seizure cessation was achieved in a similar or slightly greater proportion of children and serious adverse reactions were rare. The authors conclude levetiracetam may be an appropriate alternative second-line agent, partly because of its easier administration.
Summary written for PICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to PICUlearn members, and Peeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.